Advertisement

Rheumaderm pp 295-298 | Cite as

Enalapril (10Mg/Day) in Systemic Sclerosis

One Year, Double Blind, Randomised Study (ESS-1): Electrocardiographic Substudy—Three Months Follow-Up
  • Robert Paulisiński
  • M. Chibowska
  • A. Biłan
  • S. Ostrowski
  • J. Węglarz
  • D. Krasowska
  • J. Hanzlik
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 455)

Abstract

The ESS-1 study was designed to evaluate the long-term effects of enalapril (10mg per day) on the cardiopulmonary system of patients with systemic sclerosis (SSc). The 3 months follow-up was completed by 41 patients (23 patients in enalapril group and 18 in placebo group). We analysed conventional time domain signal averaged ECG (SAECG). Late potentials were considered to be present in QRS duration (QRS) was > 114ms or root mean square of last 40ms (RMS40) was < 20µV or terminal signal duration under 40µV (LAS40) was > 38ms at 40Hz. At the beginning of study the prevalence of abnormal SAEG parameters was similar in both groups. We observed one abnormal parameter among 13% of patients in enalapril group and 16.7% of patients in placebo group. There were 2 abnormal parameters in 26.1% of patients in enalapril group and 16.7% of patients in placebo group. After three months of treatment we did not find any patient with 2 parameters of late potentials in enalapril group and only 8.7% of patients with one such parameter. In placebo group no substantial improvement was observed.

Conclusion: The 3 months enalapril treatment seems to decrease the incidence of late potentials in patients with systemic sclerosis.

Keywords

Placebo Group Systemic Sclerosis Late Potential Scleroderma Renal Crisis Enalapril Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    LeRoy E C. Systemic Sclerosis. In: Wyngaarden JB, Smith LH Jr., eds. Cecil Textbook of Medicine. Philadelphia: WB Saunders. 2018–2033. 1988Google Scholar
  2. 2.
    Kostis JB, Seibold JR, Turkevich D, Masi AT, Grau RG, Medsger TA Jr. Et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Americal Journal of Medicine. 84:1007–1015. 1988.CrossRefGoogle Scholar
  3. 3.
    Byers RJ, Marshall DA, Freemonth AJ. Pericardial involvement in systemic sclerosis. Annals of the Rheumatic Diseases. 56:393–394. 1997.PubMedCrossRefGoogle Scholar
  4. 4.
    Moser DK, Stevenson WG, Woo MA et al. Frequency of late potentials in systemic sclerosis. American Journal of Cardiology. 67:541–543. 1991.PubMedCrossRefGoogle Scholar
  5. 5.
    Kawaguchi J, Kitabatake A. Altered signal transduction system in hypertrophied myocardium: angiotensin stimulates collagen synthesis in hypertrophied hearts. Journal of Cardiac Failure. 2(4 suppl): S13–S19. 1996.PubMedCrossRefGoogle Scholar
  6. 6.
    Zawada ET, Clements PJ, Furst DA, Bloomer HA, Paulus HE, Maxwell MH. Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron. 27:74–78. 1981.PubMedCrossRefGoogle Scholar
  7. 7.
    Vacek JL, Handlin LR, Beaufort CJ, Koenig CA. Effects of angiotensin-converting enzyme inhibitor therapy on presence of late potentials detected using signal-averaged electrocardiography in patients with congestive heart failure. Coronary Artery Disease. 4:1109–1113. 1993.PubMedCrossRefGoogle Scholar
  8. 8.
    Gonzalez-Fernandez RA, Altieri Pl, Fernandez-Martinez J, Lugo JE. Reduction in cardiac conduction velocity delay by angiotensin converting enzyme inhibition in hypertensive patients with left ventricular hypertrophy. Detection by signal averaged electrocardiography. American Journal of Hypertension. 5:896–899. 1992.PubMedGoogle Scholar
  9. 9.
    De Mello WC, Cherry RC, Manivannan S. Electrophysiologic and morfologic abnormalities in the failing heart: effect of enalapril on the electrical properties. Journal of Cardiac Failure. 3:53–61. 1997.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Robert Paulisiński
    • 1
  • M. Chibowska
    • 2
  • A. Biłan
    • 1
  • S. Ostrowski
    • 1
  • J. Węglarz
    • 1
  • D. Krasowska
    • 2
  • J. Hanzlik
    • 1
  1. 1.I Department of Internal MedicineUniversity School of MedicineLublinPoland
  2. 2.Department of DermatologyUniversity School of MedicineLublinPoland

Personalised recommendations